[Treatment of moderate persistent asthma: inhalation corticosteroids in combination with long acting beta 2-adrenergic agonists (bronchodilators) then with leukotriene receptor antagonists (anti-inflammatory agents); the 'step-3-dilemma']

There is no fulltext present in this item.

Title:	[Treatment of moderate persistent asthma: inhalation corticosteroids in combination with long acting beta 2-adrenergic agonists (bronchodilators) then with leukotriene receptor antagonists (anti-inflammatory agents); the 'step-3-dilemma']
Author(s):	Diamant, Z.; Dekhuijzen, P.N.R.
Publication year:	2003
Source:	Nederlands Tijdschrift voor Geneeskunde, vol. 147, iss. 35, (2003), pp. 1681-1685
ISSN:	0028-2162
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/123542
Display more details
Subject:	UMCN 2.1: Heart, lung and circulation
Organization:	Pulmonary Diseases
Journal title:	Nederlands Tijdschrift voor Geneeskunde
Volume:	vol. 147
Issue:	iss. 35
Page start:	p. 1681
Page end:	p. 1685
Abstract:	Apart from avoiding airway-irritating agents, the most important issue in the treatment of asthma is the suppression of airway inflammation by pharmaceutical treatment. Inhaled corticosteroids are the cornerstone of the medical treatment of asthma. Recent guidelines recommend the lowest possible effective dose for asthma management. In treatment steps 2 and 3, additive therapy of low to moderately high doses of inhalation corticosteroids in combination with add-on therapy with long-acting beta 2-adrenergic agonists (LABA) and leukotriene receptor antagonists (LTRA) has proved to be effective. LABA are inhaled agents with potent bronchodilator properties, whereas LTRA are taken orally and possess mainly systemic anti-inflammatory properties.